Avexitide: Physiology and What Research Reports

Definition: what avexitide is

Avexitide is the development name given to exendin 9-39, a 31-amino-acid peptide fragment that behaves as a competitive antagonist at the glucagon-like peptide 1 (GLP-1) receptor. That places it in the opposite pharmacological category from the widely discussed GLP-1 receptor agonists: instead of switching the receptor on, exendin 9-39 occupies the binding site and blocks the endogenous ligand. The clinical literature on avexitide has concentrated on post-bariatric hypoglycaemia (PBH), and researchers evaluated repeat subcutaneous administration of avexitide (exendin 9-39) in that population in a 2020 study reporting safety, efficacy and pharmacokinetics (PMID 32250530).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, medication or investigational compound.

Where the molecule comes from

Exendin 9-39 is not a human hormone. It is a truncated form of exendin-4, a peptide originally identified in the venom of the Gila monster lizard; the full-length molecule is a GLP-1 receptor agonist, while removal of the first eight N-terminal residues yields a fragment that binds the receptor without triggering the usual downstream signal. In the body, the receptor it targets is normally engaged by GLP-1 released from intestinal L cells after a meal.

GLP-1 physiology and why an antagonist was investigated

GLP-1 is an incretin hormone: nutrient arrival in the small intestine stimulates its secretion, and GLP-1 then potentiates glucose-dependent insulin release from pancreatic beta cells. After certain bariatric procedures, nutrients reach the distal gut more quickly and the post-meal GLP-1 response is amplified. Review articles on post-bariatric surgery hypoglycaemia described exaggerated incretin responses and inappropriate hyperinsulinaemia as central to the syndrome (PMID 35432756), and a 2023 review of drug treatments for hypoglycaemia after bariatric surgery catalogued agents with different mechanisms of action, including GLP-1 receptor blockade, as approaches investigated for this disorder (PMID 36748934).

That physiological reasoning is the reason an antagonist became interesting at all. If excess GLP-1 signalling contributes to the insulin surge that precedes a hypoglycaemic episode, then blocking the receptor is a mechanistically targeted way to test the hypothesis in humans.

How avexitide has been measured and studied

Studies of avexitide have used the standard toolkit of metabolic research rather than anything exotic:

• Provocative meal or glucose challenges with serial sampling of plasma glucose and insulin, used to define nadir glucose and peak insulin.
• Pharmacokinetic sampling, since exendin 9-39 is a small peptide with a short circulating half-life; the 2020 report examined pharmacokinetics alongside safety and efficacy endpoints of repeat subcutaneous dosing (PMID 32250530).
• Randomised, placebo-controlled crossover design, in which each participant serves as their own control; the PREVENT trial used this structure to compare avexitide with placebo in post-bariatric hypoglycaemia (PMID 33616643).
• Preclinical receptor pharmacology, including engineering work on alternative antagonists described below (PMID 37358194).

What the literature reports

The PREVENT crossover trial

The PREVENT trial was published as a randomised, placebo-controlled crossover study of avexitide for the treatment of post-bariatric hypoglycaemia, in which researchers evaluated subcutaneous avexitide at 30 mg twice daily and 60 mg once daily against placebo in adults with the condition (PMID 33616643). The study reported improvements in glycaemic endpoints relevant to hypoglycaemia, including raised glucose nadir and reduced insulin peak after a provocative meal, with avexitide compared with placebo (PMID 33616643).

Repeat subcutaneous dosing

Earlier work examined what happened when dosing was repeated rather than given once: the 2020 report described safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) in patients with post-bariatric hypoglycaemia and reported that the regimens studied were tolerated in that small population (PMID 32250530).

Beyond the peptide: antibody antagonists

A peptide antagonist with a short half-life requires frequent injection, and that limitation prompted work on longer-lasting blockers. Researchers reported the optimisation of a GLP-1 receptor antagonist antibody intended for the treatment of hyperinsulinism, describing engineering of an antagonist with properties suited to less frequent administration than a small peptide antagonist allows (PMID 37358194).

Avexitide: what studies report

Safety was an explicit, named endpoint rather than an afterthought in the clinical literature. The 2020 report was titled around safety, efficacy and pharmacokinetics of repeat subcutaneous dosing and reported tolerability findings for the regimens tested (PMID 32250530), and the PREVENT crossover trial likewise assessed avexitide against placebo with safety among its reported outcomes (PMID 33616643). Beyond those reports, the published record is limited: the trials enrolled small numbers of adults with a specific post-surgical diagnosis and ran over short periods, so long-term tolerability, rare events and effects in other populations were not characterised. Review authors discussing pharmacological options for hypoglycaemia after bariatric surgery framed the field as one where treatment options remained under investigation (PMID 36748934).

Why the term appears in peptide reading

Avexitide turns up in three recurring contexts. First, as the clearest clinical example of GLP-1 receptor antagonism, useful for understanding what the receptor does by observing what happens when it is blocked. Second, as a case study in peptide pharmacokinetics: a short-lived fragment prompted the search for engineered alternatives with longer exposure (PMID 37358194). Third, as part of the post-bariatric hypoglycaemia literature, a condition that reviews described as an under-recognised consequence of metabolic surgery (PMID 35432756).

Limits of the evidence

1. The clinical studies were conducted in adults with post-bariatric hypoglycaemia, not in healthy volunteers or general metabolic populations (PMID 33616643).
2. Trial durations were short, and the crossover design that strengthens within-person comparison also limits what can be said about sustained use (PMID 33616643).
3. Antibody-based antagonist work reported to date is preclinical development pharmacology, not human outcome data (PMID 37358194).

References

• PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia (Diabetes, Obesity & Metabolism, 2020)
• Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism (Diabetes, 2023)
• Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder (Archives of Endocrinology and Metabolism, 2023)
• Beyond diabetes remission a step further: Post bariatric surgery hypoglycemia (World Journal of Diabetes, 2022)